Home  |  Speakers  |  Agenda  |  Venue  |  Posters  |  Sponsors  |  Media  |  Register













EXAMINING SCIENTIFIC, TECHNOLOGICAL, REGULATORY & BUSINESS TRENDS & STRATEGIES TO ADVANCE PROTEIN AND ANTIBODY THERAPEUTICS & AID BIOSIMILAR DEVELOPMENT


Following the success of their 2015 meeting Global Engage is pleased to announce the 2nd Annual Biologics & Biosimilars Congress 2016 which will be held on February 1-2 in Berlin, Germany at the Maratim proArteHotel.  The meeting which attracted over 160 attendees last year will be co-located with our Biosimilars Congress which is being introduced this year after much demand. The conferences are part of our successful Drug Discovery series which includes events on synthetic biology, precision medicine, digital pathology, digital PCR and the human microbiome. 

The Biologics market is evolving with the development of new products and therapies and is expected to hit $200 billion in the next few years.  With growing commercial potential, good economic returns and lower attrition rates when compared to small molecule drugs as well as entry barriers on the manufacturing side reducing all the time, more and more companies are entering the expanding field.  The smaller, but lucrative, Biosimilars market is anticipated to grow well over $55 Billion post 2020 with growth due to numerous factors including current positive pipeline development, companies looking to take advantage of the highly lucrative third wave of biosimilar opportunity and government efforts worldwide to reduce healthcare costs.

Attracting industry, regulatory & academic experts working in all areas of protein, antibody & biosimilar research this two day interactive meeting will provide you the opportunity to take home cutting edge strategies, case study examples, regulatory guidelines, CMC considerations, to allow you to further your research, keep abreast of your competitors and stay on top of the latest technology/solution advancements and developments in the area in both Europe, US and worldwide.

This will be achieved through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, networking breaks allowing interaction with your peers, poster presentation sessions, expert led case study presentations and incisive Q&A panel discussions from a 70 strong speaker faculty examining topics on six separate tracks covering:

Biologics Congress:
Day 1 Stream 1 -
Antibody Based Therapeutics
Day 1 Stream 2 -
Protein Expression, Purification, & Characterization
Day 2 Stream 1 -
i    Antibody-Drug Conjugates

ii   Antibodies for Cancer Immunotherapy
Day 2 Stream 2 -
Protein Biotherapeutics

Biosimilars Congress:

Day 1 -             
Development Strategy, Market Access and Commercialization
Day 2 -
Overcoming Regulation & CMC Hurdles for Biosimilar Development

For a more detailed synopsis or to download the up to date agenda; please visit the agenda page.


Advisory Panel

Tudor
                        ArvinteTudor Arvinte
Therapeomic Inc &
Unversity of Geneva


Stefan DubelStefan Dübel
Technische Universität Braunschweig


Peter NeubauerPeter Neubauer
Technische Universität Berlin
(TU Berlin)



Nicolas SabarthNicolas Sabath
Baxter



Jacques DumasJacques Dumas
Sanofi



Rene HoetRene Hoet
Bayer



Karl GriswoldKarl Griswold
Dartmouth - Stealth Biologics



Jinming GuJingming Gu
Abbvie  



Nico MertensNico Mertens
Biotecnol SA

Annette SieversAnnette Sievers
Pfizer



Arne SkerraArne Skerra
TU Munchen



Ali TehraniAli Tehrani
Zymeworks Inc.



Mark ThrosbyMark Throsby
Merus



Thierry WurchThierry Wurch
Servier


[Back to Top]

   
To receive the first updates and get special offers before anyone else, please complete the form below.















Platinum Sponsor






Gold Sponsors














Silver Sponsor



Content Sponsors and Exhibitors






















See all






Copyright:  Global Engage Ltd.   Registered in England.  No: 6950636